Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.

EGFr was the only significant variable for recurrence-free survival but just failed to reach significance for overall survival (P = 0.059).

also in 279 other papers

There was a similar trend for patients whose tumours contained both EGFr and ER (Figure 4b) but this did not reach statistical significance.

also in 111,027 other papers

Tumour size showed a trend only in terms of recurrence-free survival.

also in 53,322 other papers